-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Are higher factor levels a rising consideration when selecting a hemophilia treatment?

Sponsor: Novo Nordisk
Program: Product Theaters
Saturday, December 10, 2022: 11:30 AM-12:30 PM
Hall J - Theater 6 (Ernest N. Morial Convention Center)
Stephanie Valer Seremetis, MD, Novo Nordisk and Adam R. Wufsus, PhD, Novo Nordisk
No relevant conflicts of interest to declare.
For in-person participants only
See more of: Product Theaters